Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Kurmasheva RT, Erickson SW, Earley E, Smith MA, Houghton PJ. Kurmasheva RT, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2021 Feb;68(2):e28772. doi: 10.1002/pbc.28772. Epub 2020 Oct 22. Pediatr Blood Cancer. 2021. PMID: 33089597 Free PMC article.
Testing of new agents in childhood cancer preclinical models: meeting summary.
Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Houghton PJ, et al. Clin Cancer Res. 2002 Dec;8(12):3646-57. Clin Cancer Res. 2002. PMID: 12473573
IRS-1: auditing the effectiveness of mTOR inhibitors.
Easton JB, Kurmasheva RT, Houghton PJ. Easton JB, et al. Among authors: houghton pj. Cancer Cell. 2006 Mar;9(3):153-5. doi: 10.1016/j.ccr.2006.02.027. Cancer Cell. 2006. PMID: 16530700 Free article. Review.
IGF-I mediated survival pathways in normal and malignant cells.
Kurmasheva RT, Houghton PJ. Kurmasheva RT, et al. Among authors: houghton pj. Biochim Biophys Acta. 2006 Aug;1766(1):1-22. doi: 10.1016/j.bbcan.2006.05.003. Epub 2006 Jun 7. Biochim Biophys Acta. 2006. PMID: 16844299 Review.
Predicted mechanisms of resistance to mTOR inhibitors.
Kurmasheva RT, Huang S, Houghton PJ. Kurmasheva RT, et al. Among authors: houghton pj. Br J Cancer. 2006 Oct 23;95(8):955-60. doi: 10.1038/sj.bjc.6603353. Epub 2006 Sep 5. Br J Cancer. 2006. PMID: 16953237 Free PMC article. Review.
The pediatric preclinical testing program: description of models and early testing results.
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. Houghton PJ, et al. Pediatr Blood Cancer. 2007 Dec;49(7):928-40. doi: 10.1002/pbc.21078. Pediatr Blood Cancer. 2007. PMID: 17066459
SK-NEP-1 and Rh1 are Ewing family tumor lines.
Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. Smith MA, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2008 Mar;50(3):703-6. doi: 10.1002/pbc.21099. Pediatr Blood Cancer. 2008. PMID: 17154184
Evaluation of ABT-751 against childhood cancer models in vivo.
Morton CL, Favours EG, Mercer KS, Boltz CR, Crumpton JC, Tucker C, Billups CA, Houghton PJ. Morton CL, et al. Among authors: houghton pj. Invest New Drugs. 2007 Aug;25(4):285-95. doi: 10.1007/s10637-007-9042-y. Epub 2007 Mar 24. Invest New Drugs. 2007. PMID: 17384918
591 results